299. Cystic fibrosis Clinical trials / Disease details

Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04467957 (ClinicalTrials.gov)	November 15, 2020	19/6/2020	Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis	Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis	Cystic Fibrosis	Drug: Initiation of CFTR Modulator;Drug: Hyperpolarized Xenon 129	Children's Hospital Medical Center, Cincinnati	NULL	Active, not recruiting	6 Years	21 Years	All	26	Phase 4	United States
2	NCT03593434 (ClinicalTrials.gov)	July 30, 2018	28/6/2018	Airway Clearance Therapy on Hyperpolarized 129Xenon and MRI	The Effect of Airway Clearance Therapy on Hyperpolarized 129Xenon MRI Compared With Lung Clearance Index and Spirometry in Cystic Fibrosis	Cystic Fibrosis	Drug: hyperpolarized Xenon gas	Children's Hospital Medical Center, Cincinnati	National Heart, Lung, and Blood Institute (NHLBI)	Completed	6 Years	21 Years	All	20		United States
3	NCT03482960 (ClinicalTrials.gov)	May 29, 2018	23/3/2018	Comparison of 129Xe MRI With 19F MRI in CF Lung Disease	Comparison of 129Xe MRI With 19F MRI in CF Lung Disease	Cystic Fibrosis	Drug: Hyperpolarized Xenon gas;Drug: PFP	University of North Carolina, Chapel Hill	Cystic Fibrosis Foundation	Completed	18 Years	N/A	All	11	Early Phase 1	United States
4	NCT02848560 (ClinicalTrials.gov)	March 2016	26/7/2016	Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI	Validation of MRI as a Sensitive Tool to Longitudinally Monitor CF Lung Disease Progression and Response to CFTR Modulator Therapy in Young Children With CF	Cystic Fibrosis	Drug: Hyperpolarized Xenon	Children's Hospital Medical Center, Cincinnati	National Heart, Lung, and Blood Institute (NHLBI)	Active, not recruiting	6 Years	12 Years	All	38		United States
5	NCT02740868 (ClinicalTrials.gov)	August 2015	19/8/2015	Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease	Development of Hyperpolarized Xenon-129 Lung Magnetic Resonance Imaging: Comparative Pilot Study of Healthy Volunteers and Participants With Pulmonary Disease	Cystic Fibrosis;Asthma	Drug: Xenon -129;Device: Magnetic Resonance Imaging;Device: Lung Clearance Index	The Hospital for Sick Children	NULL	Recruiting	8 Years	N/A	All	30	Phase 2	Canada
6	EUCTR2019-003052-36-GB (EUCTR)		28/02/2020	Magnetic Resonance Imaging (MRI) in Bronchiectasis	Triple Modality Functional Magnetic Resonance Lung Imaging in Cystic Fibrosis and Non-CF Bronchiectasis - MRI in Bronchiectasis	Cystic fibrosis (CF) Non-CF Bronchiectasis MedDRA version: 21.0;Level: PT;Classification code 10006445;Term: Bronchiectasis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 20.0;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: hyperpolarized xenon-129 Product Name: hyperpolarized xenon-129	The University of Nottingham	NULL	NA			Female: yes Male: yes	40	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom